BioVaxys Technology Corp. BVAXF

Primary Symbol: C.BIOV

BioVaxys Technology Corp. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on improving patient lives with novel immunotherapies based on the DPX immune-educating technology platform and its HapTenix neoantigen tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization and other immunological fields. The Company's clinical-stage pipeline includes maveropepimut-S, which is in phase II clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using its HapTenix neoantigen tumor cell construct platform for treating refractive late-stage ovarian cancer. The Company is also leveraging its expertise in tumor immunology by creating a unique library of T-lymphocytes and other datasets post-vaccination with its personalized immunotherapeutic vaccines to identify new targetable tumor antigens.

CSE:BIOV - Post by User

BioVaxys Technology Corp. > Advice to any remaining shorts same as before

<< Previous

Bullboard Posts

Next >>

Comment by frankmanon Jan 14, 2022 2:25pm

51 Views

Post# 34318183

RE:RE:Advice to any remaining shorts same as before

A tiny spec of the float

Report Date	Volume	Change	Shares Issued	% Float
2021-12-31	57,763	-18,344	71,203,091	0.08
2021-12-15	76,107	-232,461	71,203,091	0.11
2021-11-30	308,568	266,451	71,203,091	0.43